west china medical publishers
Author
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Author "Fan JunMing" 1 results
  • Shenkang Capsule in the Treatment of Chronic Glomerulonephritis ( Qiyinliangxu Syndrome):A Double Blind, Randomized Controlled Trial

    Objective To assess the effectivess and safety of Shenkang capsule in the treatment of chronic glomerulonephritis (Qiyinliangxu Syndrome). Methods A double blind, double dummy and randomized controlled method was adopted. A total of 96 patients were randomized to the treatment group (Shenkang capsule, 2 capsules, twice a day) and the control group (Shenyankang capsule, 2 capsules, twice a day). The therapeutic course for both groups was 2 months. Results All the results were analyzed on the basis of retention-to-treat(ITT) and per-protocol-population (PP). For effect of chronic glomerulonephritis in the treatment group, the clinical control rates were 12.86% (9/70) with ITT analysis and 14. 75% (9/61) with PP analysis; the good improvement rates were 12. 86% (9/70) with ITT analysis and 14. 75% (9/61) with PP analysis; the total effective rates were 48. 58% (34/70) and 55.73% (34/61). In the control group, the clinical control rates were 4. 17% (1/24) with ITT analysis and 5.00% (1/20) with PP analysis respectively; the good improvement rates were 4. 17% (1/24) with ITT analysis and 5.00% (1/20) with PP analysis respectively; the total effective rates were 45. 83% (11/24) with ITT analysis and 55.00% (11/20) with PP analysis. There was no statistical difference between the two groups (P〉0.05). For Qiyinliangxu syndrome improvement, in the treatment group, the clinical control rate and good improvement rate were 18. 57% (13/70) with ITT analysis and 21.31% (13/61) with PP analysis respectively; the total effective rates were 81.43% (57/70) with ITT analysis and 93. 44% (57/61) with PP analysis respectively; In the control group, the clinical control rate and good improvement rate were 20. 84% ( 5/24 ) with ITT analysis and 25.00% (5/20 ) with PP analysis respectively; the total effective rates were 75. 00% (18/24) with ITT analysis and 85. 00% (17/20) with PP analysis respectively. The results showed no statistical difference between the two groups (P 〉0. 05). No adverse effects were found. Conclusions No statistical difference was detected between Shengkang capsule and Shenyan capsule groups. No obvious toxic adverse effects were found.

    Release date:2016-09-07 02:26 Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content